Active Biotech AB Interim Report January - September 2010

LUND, SWEDEN--(Marketwire - October 27, 2010) -

* Laquinimod - Phase III trials proceeding as planned, results from Phase II extension study published in scientific journal

* TASQ - preparations ongoing for start of Phase III in first half of 2011

* ANYARA - ongoing phase III trial expected to be concluded in first half of 2012

* 57-57 - exploratory SLE clinical trial completed

* ISI - project continuing according to plan

* RhuDex™ - preparations for continued clinical development in progress

* Net sales of SEK 8.5 M (7.7)

* Operating loss of SEK 149.7 M (loss: 164.6)

* Loss after tax SEK 156.8 M (loss: 165.1)

* Loss per share for the period amounted to SEK 2.40 (loss: 2.90)

This report is also available at www.activebiotech.com

[HUG#1455517]

Active Biotech AB Interim Report January-September 2010: http://hugin.info/1002/R/1455517/395393.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE